Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)

Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)	Sep. 30, 2024 USD ($)
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations	$ 128,150,000
Astellas Collaboration Agreement
Revenue
Aggregate transaction price of the contract modification	42,365,000
Aggregate amount of the transaction price that is allocated to performance obligations	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details